9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Estimated reading time: 1 min

Condition

Advanced Malignant Solid Neoplasm|Advanced Peritoneal Malignant Mesothelioma|Advanced Pleural Malignant Mesothelioma|Recurrent Malignant Solid Neoplasm|Recurrent Peritoneal Malignant Mesothelioma|Recurrent Pleural Malignant Mesothelioma|Stage III Non-Small Cell Lung Cancer|Stage III Ovarian Cancer|Stage III Pleural Mesothelioma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIA Ovarian Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIB Ovarian Cancer|Stage IIIC Ovarian Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Ovarian Cancer|Stage IV Pleural Mesothelioma|Thymoma|Unresectable Solid Neoplasm

Estimated Enrollment: 58

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: NCI-2015-00127|PHI-76|9837|P30CA033572|UM1CA186689|UM1CA186705|UM1CA186717|ZIABC011078

Study First Received: August 27, 2015

Last Updated: March 23, 2017

Estimated Primary Completion Date: August 2017

Primary Outcome Measures:

Dose-limiting toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Arm A)|Response rate using RECIST (Arm B)|Establishment of pleural and peritoneal effluent-derived cell lines|Objective clinical response|Pharmacokinetic (PK) parameter|Response of cultured pleural and peritoneal mesothelioma cells to cisplatin, pemetrexed, and methoxyamine

Sponsors and Collaborators:

National Cancer Institute (NCI)

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT02535312

Was this article helpful?
Views: 58